Comparative Pharmacology
Head-to-head clinical analysis: INDERIDE 80 25 versus RENESE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INDERIDE 80 25 versus RENESE.
INDERIDE-80/25 vs RENESE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
INDERIDE-80/25 is a combination of propranolol (a non-selective beta-adrenergic receptor antagonist) and hydrochlorothiazide (a thiazide diuretic). Propranolol blocks beta-1 and beta-2 adrenergic receptors, reducing heart rate, myocardial contractility, and renin release, thereby lowering blood pressure. Hydrochlorothiazide inhibits the sodium-chloride symporter in the distal convoluted tubule of the kidney, increasing excretion of sodium, chloride, and water, reducing plasma volume.
Thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, reducing sodium and chloride reabsorption, leading to increased diuresis and vasodilation.
One tablet (80 mg propranolol/25 mg hydrochlorothiazide) orally twice daily.
Initial 2.5-5 mg orally once daily; increase by 2.5-5 mg every 2-4 weeks up to 20 mg/day as needed.
None Documented
None Documented
Propranolol: 3-6 hours (single dose), prolonged with chronic dosing (up to 12 hours). Hydrochlorothiazide: 6-15 hours; prolonged in renal impairment.
13–15 hours; prolonged in renal impairment (CrCl <30 mL/min: up to 30–40 hours).
Renal: 40% unchanged propranolol; 60% as metabolites. Biliary/fecal: minimal (less than 1%). Hydrochlorothiazide: renal 95% unchanged.
Renal: ~85% unchanged; fecal: ~15% (via bile).
Category C
Category C
Beta Blocker and Thiazide Diuretic
Thiazide Diuretic